onartuzumab

Ligand id: 8966

Name: onartuzumab

No information available.
Summary of Clinical Use
In early 2014, a phase III study of onartuzumab (in combination with erlotinib; NCT01456325) in patients with MET-positive non-small cell lung cancer was terminated due to a lack of clinically meaningful efficacy [1,7]. Additional Phase III studies evaluating onartuzumab's antineoplastic activity in MET-positive lung, gastric and other solid cancers are ongoing [6]. Click here to link to ClinicalTrials.gov's list of Phase III onartuzumab trials.
Mechanism Of Action and Pharmacodynamic Effects
MET proteins dimerise upon hepatocyte growth factor (HGF) binding. This triggers a signalling cascade that promotes cell growth, division and migration. Activation of the MET pathway has been proposed as a mechanism of tumour growth and metastasis [3,5].